BIND Therapeutics Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass. (EON: Enhanced Online News) BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, announced today the pricing of its initial public offering of 4,700,000 shares of its common stock at a public offering price of $15.00 per share, before underwriting discounts [...]